Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4876937
Max Phase: Preclinical
Molecular Formula: C14H12F6N2O3
Molecular Weight: 370.25
Molecule Type: Unknown
Associated Items:
ID: ALA4876937
Max Phase: Preclinical
Molecular Formula: C14H12F6N2O3
Molecular Weight: 370.25
Molecule Type: Unknown
Associated Items:
Canonical SMILES: C[C@@H]1OC(=O)NN=C1c1ccc(OCCC(F)(F)F)c(C(F)(F)F)c1
Standard InChI: InChI=1S/C14H12F6N2O3/c1-7-11(21-22-12(23)25-7)8-2-3-10(9(6-8)14(18,19)20)24-5-4-13(15,16)17/h2-3,6-7H,4-5H2,1H3,(H,22,23)/t7-/m0/s1
Standard InChI Key: JKGNEDMIYWJYDW-ZETCQYMHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 370.25 | Molecular Weight (Monoisotopic): 370.0752 | AlogP: 3.87 | #Rotatable Bonds: 4 |
Polar Surface Area: 59.92 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 1 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 10.52 | CX Basic pKa: | CX LogP: 3.65 | CX LogD: 3.65 |
Aromatic Rings: 1 | Heavy Atoms: 25 | QED Weighted: 0.82 | Np Likeness Score: -0.58 |
1. Sabnis RW.. (2021) Novel Dihydrooxadiazinones as PDE3 Inhibitors for Treating Cancer., 12 (7.0): [PMID:34267873] [10.1021/acsmedchemlett.1c00317] |
Source(1):